Drug Search Results
More Filters [+]

BLX-028914

Alternative Names: blx-028914, blx028914, blx 028914
Latest Update: 2013-03-13
Latest Update Note: Clinical Trial Update

Product Description

BLX-028914, a selective phosphodiesterase-4 (PDE4) inhibitor with a promising safety profile,is currently under development for treatment of airway diseases by Orexo AB, Sweden. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00758446)

Mechanisms of Action: PDE4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Dart NeuroScience
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BLX-028914

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Rhinitis, Allergic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2008-001179-30

P2

Completed

Rhinitis, Allergic

2008-12-18

OX914-001

P2

Completed

Rhinitis, Allergic

2008-12-01

Recent News Events

Date

Type

Title